深圳粒影生物科技有限公司重組三螺旋結構膠原蛋白已正式被納入國際化妝品原料（INCI）目錄（INCI編號40302），這是膠原蛋白首次被INCI列為三聚體，也是首個(gè)被收錄的重組三螺旋膠原蛋白，并將“三螺旋”直接接受為有結構的膠原蛋白商品名，這標志著(zhù)粒影生物三螺旋重組膠原蛋白正式走向國際市場(chǎng)。
Shenzhen LiYing Biotechnology Co., Ltd.'s recombinant triple-helix collagen has been officially included in the International Nomenclature of Cosmetic Ingredients (INCI) directory (INCI No. 40302). This marks the first time collagen has been listed by INCI as a trimer, with the "Tri-helix" directly recognized as structured collagen. It signifies that LIYING BIO's recombinant triple-helix collagen is now officially entering the international market.
圖一：INCI分配信
Figure 1. INCI Assignment Letter
INCI名稱(chēng)是國際公認用于識別化妝品成分的系統名稱(chēng)，由國際命名委員會(huì )(International Nomenclature Committee，簡(jiǎn)稱(chēng)為INC)審核和分配，并由美國個(gè)人護理產(chǎn)品協(xié)會(huì )(Personal Care Products Council，簡(jiǎn)稱(chēng)為PCPC)發(fā)布在《國際化妝品成分字典和手冊》中。這些名稱(chēng)在全球范圍內被認可，用于識別化妝品成分，旨在確?；瘖y品成分的準確性和一致性。
The INCI name is an internationally recognized system for identifying cosmetic ingredients. They are reviewed and assigned by the International Nomenclature Committee (INC), and published by the Personal Care Products Council (PCPC) in the International Cosmetic Ingredient Dictionary and Handbook. These names are globally accepted for identifying cosmetic ingredients, ensuring accuracy and consistency in cosmetic formulations.
粒影生物的三螺旋膠原蛋白結構穩定、功效強，生物相容性好，具有顯著(zhù)的抗衰、修復、抗皺和美白功效，不僅能應用在護膚和日化領(lǐng)域，還能夠應用于臨床醫學(xué)，如醫美填充、創(chuàng )面修復及骨科等領(lǐng)域。此外，其耐高溫特性使其能夠適應多種生產(chǎn)與應用環(huán)境。
LIYING BIO's Tri-helix collagen features a stable structure, high efficacy, and excellent biocompatibility, delivering remarkable anti-ageing, reparative, anti-wrinkle, and brightening benefits. Beyond skincare and personal care applications, it is also suitable for clinical medical uses, such as aesthetic fillers, wound repair, and orthopaedic treatments. Additionally, its heat-resistant properties enable versatile adaptation to diverse production and application environments.
圖二：結構與功能驗證
Figure 2. Structural and Functional Verification
圖三：毒理檢測報告
Figure 3. Toxicology Test Report
粒影生物通過(guò)生物合成的方法，結合人工智能計算、設計、改造獲得高活性蛋白質(zhì)，構建高適配工程菌株，實(shí)現了具有三螺旋結構的重組人源化膠原蛋白的成功表達和高效生產(chǎn)，并形成以ZL 202410624084.X等十余項核心專(zhuān)利、二十多項外圍專(zhuān)利的技術(shù)包，同時(shí)布局海外專(zhuān)利，筑起專(zhuān)利墻。憑借這些創(chuàng )新成果，粒影生物獲得了多項榮譽(yù)與資質(zhì)。
LIYING BIO employs synthetic-biology approaches, integrating AI-powered computation, design, and modification to develop highly active proteins. The company has successfully constructed high-efficiency engineered bacterial strains capable of expressing and producing recombinant humanized collagen with a stable Tri-helix structure. Backed by a robust IP portfolio - including core patents such as ZL 202410624084.X (with over 10 core patents and 20+ peripheral patents) and strategic international patent filings - LIYING BIO has established a comprehensive patent protection system. These technological breakthroughs have earned the company numerous prestigious awards and certifications in recognition of its innovations.
圖四：自主發(fā)明專(zhuān)利
Figure 4: Independent Invention Patents
圖五：獲獎情況
Figure 5: Awards
圖六：獎勵證書(shū)
Figure 6: Award Certificate
目前，粒影生物的三螺旋膠原蛋白已經(jīng)成功應用于市場(chǎng)，并在多個(gè)領(lǐng)域展現出巨大的應用潛力，自主研發(fā)的護膚品牌Tri-helix于2024年底正式上線(xiàn)，并受到消費者一致好評。
Currently, LIYING BIO 's Tri-helix collagen has been successfully commercialized and demonstrates significant potential across multiple applications. The company's proprietary skincare brand, Tri-helix, officially launched in late 2024 and has received unanimous acclaim from consumers.
圖七：顧客反饋
Figure 7：customer feedback
